Morphic Holding stock was surging Monday after pharmaceutical giant Eli Lilly agreed to acquire the biopharmaceutical company ...
Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the ...
Eli Lilly agreed to buy biopharmaceutical firm Morphic for roughly $3.2 billion, sending shares of Morphic skyrocketing ...
(Bloomberg) — Eli Lilly agreed to buy Waltham-based gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some ...
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda ...
The acquisition bolsters Lilly's gastroenterology portfolio, with a focus on developing new treatments for inflammatory bowel ...
Eli Lilly & Co. has announced the acquisition of Morphic Holding Inc., a US-based biotech company specializing in treatments ...
Eli Lilly N/A will acquire Morphic Holding N/A for $3.2-billion in cash, the companies said on Monday, giving the U.S.
Eli Lilly says it will acquire a Waltham-based drug company that's working on a treatment for inflammatory bowel disease.
Eli Lilly LLY-0.60%decrease; red down pointing triangle has agreed to buy biopharmaceutical company Morphic Holding MORF 0.02%increase; green up pointing triangle for $3.2 billion in a deal that ...